Graz, Austria-based ProtAffin Biotechnologie AG has completed a second closing of its series A financing. The Entrepreneurs Fund BV invested 1.3 million euros ($1.9 million) in the second closing, in addition to the 2.6 million euros first closing in May 2007 from Aescap Venture Management BV and Z-Cube Srl. This brings the total funds raised in the series A financing to 4.0 million euros.
The company will use the funds to progress its lead product PA401 through preclinical development and to further validate and broaden its CellJammer discovery technology. While heparin is a glycan-based product successfully used in preventing coagulation for over 40 years, the therapeutic potential of targeting protein-glycan interactions in inflammation and cancer has so far been under-exploited, noted ProtAffin, which is using its CellJammer technology to develop biological products which have an anti-inflammatory activity by binding to heparin-like glycans driving inflammation.
The company's lead product, PA401, has been derived from interleukin-8, and has shown potent efficacy in a number of in vivo models of inflammatory diseases. ProtAffin plans to develop PA401 for ischemia/reperfusion injury in the setting of kidney transplantation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze